These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27394932)

  • 41. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder.
    Brown ES; Todd JP; Hu LT; Schmitz JM; Carmody TJ; Nakamura A; Sunderajan P; Rush AJ; Adinoff B; Bret ME; Holmes T; Lo A
    Am J Psychiatry; 2015 Oct; 172(10):1014-21. PubMed ID: 25998279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription.
    Dürsteler-MacFarland KM; Farronato NS; Strasser J; Boss J; Kuntze MF; Petitjean SA; Bürki C; Wiesbeck GA
    J Clin Psychopharmacol; 2013 Feb; 33(1):104-8. PubMed ID: 23277248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties.
    Gao Y; LaFleur D; Shah R; Zhao Q; Singh M; Brimijoin S
    Chem Biol Interact; 2008 Sep; 175(1-3):83-7. PubMed ID: 18514640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.
    Brown ES; Gorman AR; Hynan LS
    J Clin Psychopharmacol; 2007 Oct; 27(5):498-502. PubMed ID: 17873684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence.
    Reid MS; Angrist B; Baker S; Woo C; Schwartz M; Montgomery A; Majewska D; Robinson J; Rotrosen J
    Addiction; 2005 Mar; 100 Suppl 1():32-42. PubMed ID: 15730348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation and in vivo characterization of a cocaine hydrolase engineered from human butyrylcholinesterase for metabolizing cocaine.
    Xue L; Hou S; Tong M; Fang L; Chen X; Jin Z; Tai HH; Zheng F; Zhan CG
    Biochem J; 2013 Aug; 453(3):447-54. PubMed ID: 23849058
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study.
    Sofuoglu M; Poling J; Gonzalez G; Gonsai K; Oliveto A; Kosten TR
    Exp Clin Psychopharmacol; 2007 Oct; 15(5):453-60. PubMed ID: 17924779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.
    Ciraulo DA; Knapp C; Rotrosen J; Sarid-Segal O; Ciraulo AM; LoCastro J; Greenblatt DJ; Leiderman D
    Addiction; 2005 Mar; 100 Suppl 1():23-31. PubMed ID: 15730347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy.
    Gorelick DA
    Drug Alcohol Depend; 1997 Dec; 48(3):159-65. PubMed ID: 9449014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study.
    Kablinger AS; Lindner MA; Casso S; Hefti F; DeMuth G; Fox BS; McNair LA; McCarthy BG; Goeders NE
    J Psychopharmacol; 2012 Jul; 26(7):973-81. PubMed ID: 22236504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
    Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
    Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.
    Mooney ME; Herin DV; Specker S; Babb D; Levin FR; Grabowski J
    Drug Alcohol Depend; 2015 Aug; 153():94-103. PubMed ID: 26116930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a Highly Efficient Long-Acting Cocaine Hydrolase Entity to Accelerate Cocaine Metabolism.
    Zheng F; Jin Z; Deng J; Chen X; Zheng X; Wang G; Kim K; Shang L; Zhou Z; Zhan CG
    Bioconjug Chem; 2022 Jul; 33(7):1340-1349. PubMed ID: 35767675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rational design of an enzyme mutant for anti-cocaine therapeutics.
    Zheng F; Zhan CG
    J Comput Aided Mol Des; 2008 Sep; 22(9):661-71. PubMed ID: 17989928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users.
    Askalsky P; Kalapatapu RK; Foltin RW; Comer SD
    Am J Drug Alcohol Abuse; 2015 Mar; 41(2):161-5. PubMed ID: 25321637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice.
    Murthy V; Gao Y; Geng L; LeBrasseur NK; White TA; Parks RJ; Brimijoin S
    Vaccine; 2014 Jul; 32(33):4155-62. PubMed ID: 24892251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical validation of reduction in cocaine frequency level as an endpoint in clinical trials for cocaine use disorder.
    Roos CR; Nich C; Mun CJ; Babuscio TA; Mendonca J; Miguel AQC; DeVito EE; Yip SW; Witkiewitz K; Carroll KM; Kiluk BD
    Drug Alcohol Depend; 2019 Dec; 205():107648. PubMed ID: 31677490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Percentage of negative urine drug screens as a clinically meaningful endpoint for RCTs evaluating treatment for cocaine use.
    Loya JM; Babuscio TA; Nich C; Alessi SM; Rash C; Kiluk BD
    Drug Alcohol Depend; 2023 Jul; 248():109947. PubMed ID: 37276806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.